DWA
OVID icon

Dorsey Wright & Associates’s Ovid Therapeutics OVID Stock Holding History

Dorsey Wright & Associates’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,336
Closed -$10K – 350
2020
Q2 		$10K Buy
+1,336
New +$6.25K ﹤0.01% 255

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Dorsey Wright & Associates's OVID Position: Q3 2020 in Review

Dorsey Wright & Associates sold out of Ovid Therapeutics (OVID) in Q3 2020, closing a stake of 1,336 shares — an estimated $10K sold.

Dorsey Wright & Associates first reported a position in OVID in Q2 2020 and held it in 1 quarter. The position peaked at $10K in Q2 2020. 91 funds tracked by Wall St. Rank hold OVID as of Q3 2020.

  • Dorsey Wright & Associates reported no remaining Ovid Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,336 Ovid Therapeutics shares in Q3 2020, an estimated $10K.
  • Dorsey Wright & Associates first reported a position in Ovid Therapeutics in Q2 2020 and held it in 1 quarter.
  • Dorsey Wright & Associates's Ovid Therapeutics position peaked at $10K in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2020.

Based on Dorsey Wright & Associates's 13F filing for Q3 2020, filed 28 Oct 2020.